EVO Stock Analysis: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$2.89
-0.06 (-2.03%)
▼
5d:
+0.7%
30d:
-7.37%
90d:
-11.62%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EVO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: EVO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $2.89, which is considered slightly low relative to its 30-day fair value range of $2.82 to $3.12. From a valuation perspective, the stock is trading at a discount (Forward PE: -19.0) compared to its historical average (45.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVO is in a downtrend. Immediate support is located at $2.75, while resistance sits at $3.08.
Market Sentiment: EVO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.19 (+76.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EVO is in a downtrend. Immediate support is located at $2.75, while resistance sits at $3.08.
Market Sentiment: EVO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.19 (+76.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.82 -
$3.12
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 76.0% below Wall St target ($5.19)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.82 -
$3.12
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.75
Resistance Level
$3.08
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.03
Wall Street Target
$5.19
(+76.0%)
Revenue Growth (YoY)
-21.7%
Profit Margin
-26.0%
PE vs Historical
-19.0 vs 45.3
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
